China launch lifts Biome while EBR’s WiSE rollout slows
EBR’s WiSE rollout slowed sharply as debt worries hit the stock, while Biome gained on a planned China launch.
Across aged care and healthcare technology, investors weighed stronger revenue against cash needs, trial delays and regulatory hurdles.
- EBR Systems fell 24% after September WiSE procedures dropped to about half the July-August average.
- AdAlta rose 16.67% after receiving a larger-than-expected A$1.396 million research refund.
- Biome gained 15.63% after agreeing to target A$2 million in first-year China purchases.
- Promisia lifted FY27 earnings guidance after occupancy stayed above 95% and declared its first interim dividend.
- Several biotech companies reached trial or regulatory milestones, but most still face long waits before sales.
Add us as a preferred source on Google
EBR Systems (ASX:EBR) was the week’s biggest mover, falling 24.00% after September WiSE implants dropped to about half the average seen in July and August. AdAlta (ASX:1AD) rose 16.67% after receiving a A$1.396 million research refund. Biome Australia (ASX:BIO) gained 15.63% after setting a A$2 million first-year purchase target for a planned China launch.
EBR sold 40 WiSE systems in the third quarter, taking total implants to 157. However, the September slowdown raised concern because the company lost sales pace just as it faces a US$16.6 million quarterly loss. EBR held US$93.2 million in cash and investments at 30 September, but US$41.8 million of debt is due within 12 months. Its filing also warned that there may be doubt about its ability to keep operating without new funding or stronger sales.
Growth plans meet the cash test
Biome’s China agreement gives H&S Global exclusive mainland distribution rights through cross-border online platforms. The launch is planned for early 2027. The A$2 million purchase target is larger than Biome’s full FY26 international sales, but the company must provide marketing and operating support equal to 25% of first-year invoiced sales. Future exclusivity depends on meeting purchase targets.
AdAlta’s research refund gives it extra cash before a December manufacturing run for its EW-001 CAR-T treatment. The company also expects minutes from a US regulatory meeting in early December. The refund is useful, but it does not yet show that the treatment works or that regulators will allow human testing to progress.
Aged-care operators produced the clearest earnings improvements. Promisia Healthcare (NZX:PHL) lifted underlying EBITDAF, a measure of operating profit before certain costs, by 50% to NZ$3.83 million. Occupancy stayed above 95%, free cash flow reached NZ$1.02 million and the company declared its first interim dividend. It also raised FY27 EBITDAF guidance to at least NZ$9 million. The Chatswood purchase lifted the bank loan-to-value ratio to about 43%, so debt will need watching.
Radius Health (NZX:RAD) increased first-half profit by 27% to NZ$8 million and raised its interim dividend by 10% to 1.1 cents per share. It lifted its FY27 earnings target above NZ$30 million. Net bank debt rose to NZ$90.5 million after buying and developing assets, including the first 100-bed home in a planned 10-home programme.
Trials move forward, but results remain distant
Several smaller healthcare companies reported progress without clinical proof yet. Neurizon (ASX:NUZ) moved the first participant in its 250-person ALS study into an optional extension after 36 weeks of treatment. Results from the main study are expected in late June 2027. Miro Sciences (ASX:MSX) completed a regulator’s inspection of its manufacturing site for StemSmart, but the inspection did not approve the trial or confirm a successful audit.
Cleo Diagnostics (ASX:COV) installed three testing instruments in a US laboratory before a planned study of about 1,470 samples. The work is intended to support a US approval application in the first half of 2027. Nanosonics (ASX:NAN) won another US clearance for its CORIS endoscope cleaning system, while Memphasys (ASX:MEM) signed its first New Zealand Felix contract for at least 1,200 IVF cartridges. Neither company gave a sales forecast.
Other announcements carried more immediate corporate or financial risk. Genetic Signatures (ASX:GSS) faces a Takeovers Panel challenge from 18.46% shareholder BCAL Diagnostics over its proposed Microba merger. No Panel has yet opened proceedings. Imricor Medical Systems (ASX:IMR) signed two US hospital customers, but its cash balance fell against a US$21.4 million nine-month operating outflow. Uscom (ASX:UCM) had only A$2,000 in cash and no customer receipts at 30 September while it searches for a new acquisition.
This Week's Sector Wraps
Compare performance across the market
Bottom Line?
The next test will be whether EBR can restore monthly WiSE procedures after the September slowdown. Investors will also watch Promisia and Radius as new property spending increases debt, while Biome prepares its early 2027 China launch. Clinical companies are moving towards trials and regulatory submissions, but their major value tests remain in 2027.
Questions in the middle?
- Can EBR lift WiSE procedures again before its debt due within 12 months becomes a larger problem?
- Will Biome’s China sales reach the A$2 million target after the company funds 25% of first-year invoiced value?
- Will the Takeovers Panel allow the Genetic Signatures-Microba merger process to continue unchanged?
Sources
14This wrap draws on announcements from 14 companies. For the full story and each verified source, see the company's own article:
ASX:1AD, ASX:AVR, ASX:BIO, ASX:COV, ASX:CYP, ASX:EBR, ASX:GSS, ASX:IMR, ASX:MAP, ASX:MEM, ASX:MSX, ASX:NAN, ASX:NUZ, ASX:UCM